Jean - Antoine RIBEIL
Hôpital Necker - Enfants Malades, Public Hospitals of Paris · bluebird bio, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jean - Antoine RIBEIL as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:09 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02212535 · Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell PatientsAssistance Publique - Hôpitaux de Paris · completed · Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia · study director
- Ph1/Ph2NCT02151526 · A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell DiseaseGenetix Biotherapeutics Inc. · completed · Beta-Thalassemia Major, Sickle Cell Disease · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:09 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.N Engl J Med · 2018526 citationsRCR 19.0
- Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.N Engl J Med · 2022362 citationsRCR 26.3
- Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.Haematologica · 201893 citationsRCR 3.4
- Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.Nat Med · 202291 citationsRCR 6.4
- Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.Haematologica · 201978 citationsRCR 3.1
- First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor.Adv Ther · 201150 citationsRCR 1.7
- Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target.Br J Haematol · 201744 citationsRCR 1.9
- 35 citationsRCR 1.5
- 29 citationsRCR 1.0